Some Pneumococcal Serotypes Are More Frequently Associated with Relapses of Acute Exacerbations in COPD Patients

Arnau Domenech1,2, Carmen Ardanuy1,2*, Roman Pallares2,3, Immaculada Grau2,3, Salud Santos4, Adela G. De la Campa2,5,6, Josefina Liñares1,2

1 Department of Microbiology, Hospital Universitari de Bellvitge-IDIBELL-Barcelona University, Barcelona, Spain, 2CIBERES (Ciber de Enfermedades Respiratorias), ISCIII, Madrid, Spain, 3Department of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL-Barcelona University, Barcelona, Spain, 4Department of Pneumology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain, 5Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain, 6Consejo Superior de Investigaciones Científicas, CSIC, Madrid, Spain

Abstract

Objectives: To analyze the role of the capsular type in pneumococci causing relapse and reinfection episodes of acute exacerbation in COPD patients.

Methods: A total of 79 patients with 116 recurrent episodes of acute exacerbations caused by S. pneumoniae were included into this study (1995–2010). A relapse episode was considered when two consecutive episodes were caused by the same strain (identical serotype and genotype); otherwise it was considered reinfection. Antimicrobial susceptibility testing (microdilution), serotyping (PCR, Quellung) and molecular typing (PFGE/MLST) were performed.

Results: Among 116 recurrent episodes, 81 (69.8%) were reinfections, caused by the acquisition of a new pneumococcus, and 35 (30.2%) were relapses, caused by a pre-existing strain. Four serotypes (9V, 19F, 15A and 11A) caused the majority (60.0%) of relapses. When serotypes causing relapses and reinfection were compared, only two serotypes were associated with relapses: 9V (OR 8.0; 95% CI, 1.34–85.59) and 19F (OR 16.1; 95% CI, 1.84–767.20). Pneumococci isolated from relapses were more resistant to antimicrobials than those isolated from the reinfection episodes: penicillin (74.3% vs. 34.6%, p<0.001), ciprofloxacin (25.7% vs. 9.9%, p<0.027), levofloxacin (22.9% vs. 7.4%, p=0.029), and co-trimoxazole (54.3% vs. 25.9%, p<0.001).

Conclusions: Although the acquisition of a new S. pneumoniae strain was the most frequent cause of recurrences, a third of the recurrent episodes were caused by a pre-existing strain. These relapse episodes were mainly caused by serotypes 9V and 19F, suggesting an important role for capsular type.

Citation: Domenech A, Ardanuy C, Pallares R, Grau I, Santos S, et al. (2013) Some Pneumococcal Serotypes Are More Frequently Associated with Relapses of Acute Exacerbations in COPD Patients. PLoS ONE 8(3): e59027. doi:10.1371/journal.pone.0059027

Editor: Lorenzo Aguilar, School of Medicine, Univ. Complutense, Spain

Received December 19, 2012; Accepted February 8, 2013; Published March 11, 2013

Copyright: © 2013 Domenech et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social [PI 0901904], by grants [BIO2008-02154 and BIO2011-25343] from Plan Nacional de I+D+I of Ministerio de Ciencia e Innovación, and by CIBER de Enfermedades Respiratorias, CIBERES; [CB06/06/0037], run by the Instituto de Salud Carlos III (ISCIII), Madrid, Spain. A. D. was supported by a grant from Formación de Profesorado Universitario (FPU; Ministerio de Educación, Spain). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: c.ardanuy@bellvitgehospital.cat

Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in developed countries [1]. Approximately 50% of acute exacerbation episodes of COPD are caused by bacterial pathogens, mainly Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis [2]. The development of an acute exacerbation episode caused by S. pneumoniae is thought to be associated with the acquisition of a new strain, although scarce information is available [3].

Capsular type, the principal pneumococcal virulence factor, had been related to the ability of pneumococci to cause invasive disease or colonization [4]. However, the aetiological role of pneumococcal serotypes in relapse episodes of COPD patients remains to be determined.

The aims of this study were to analyse the relationship between serotype and genotype and the ability to cause relapse or reinfection episodes in patients with COPD. In addition, we have explored the influence of previous antimicrobial therapy in this occurrence.

Results

Epidemiological and clinical data

A total of 79 COPD patients were included in the study. Their mean age was 69 (SD ±6) years, and 77 (97.5%) of them were males. In terms of COPD severity there was 1 patient with mild
(1.3%), 14 patients with moderate (17.7%), 18 patients with severe (22.0%) and 39 patients with very severe (49.4%) airflow obstruction. The GOLD status of the remaining 7 patients was not available.

Fifty-two patients had ≥1 reinfections (caused by pneumococci with different serotype and genotype), 16 had ≥1 relapses (caused by the same pneumococcus), and the remaining 11 patients had both relapses and reinfections. No differences were observed as regards the age of patients with relapse or reinfection (69.9±9 vs. 70.5±9, respectively), nor in terms of COPD severity (GOLD II: 71.7±13 vs. 69.2±8, respectively; GOLD III: 66.4±27 vs. 70.6±11, respectively; and GOLD IV: 69.1±9 vs. 69.4±8, respectively).

Finally, a total of 116 recurrent episodes from the 79 patients were studied; of these, 35 (30.2%) were relapses and 81 (69.8%) reinfections. The mean time between episodes was 166±96 days, being shorter among relapses (133±89 days) than among reinfections (181±96 days; P=0.020). Table 1 shows the distribution of the episodes based on the mean time between episodes. When the consecutive episodes occurred during a period ≤120 days, significantly higher frequency of relapse episodes was observed (57.1% vs. 35.8%, P=0.033). Whereas, when the period of time between episodes was higher than 240 days the frequency of reinfection episodes was higher (14.3% vs. 30.9%, P=0.061).

In 13 of the 35 (37.1%) relapses and in 31 of the 81 (38.3%) reinfections, pneumococcal strains were isolated together with other potential pathogens.

However, P. aeruginosa was more frequently isolated from relapses than from reinfections (17.1% vs. 7.4%, respectively; P=0.108), whereas H. influenzae was more closely associated with reinfections (2.9% vs. 23.5%; P=0.006).

Serotyping and genotyping

Four of the 31 serotypes detected caused 60.0% of relapses. These serotypes were 9V (17.1%), 19F (17.1%), 15A (14.3%) and 11A (11.4%). The most frequent serotypes isolated from reinfections were 15A (8.6%), 16F (7.4%), 3 (6.2%) and 33F (6.2%). Statistically significant differences were only observed in two serotypes associated with relapses when compared with reinfections: 9V (OR 8.0; 95% CI, 1.34–85.59) and 19F (OR 16.1; 95% CI, 0.00–186.68) [Table 2].

Serotypes included in the polysaccharide pneumococcal 23-valent (23vPPV) accounted for 74.3% (n=26) of relapses, and 56.8% (n=46) of reinfections. Whereas, the coverage of the 10-valent (PCV-10) and 13-valent (PCV-13) pneumococcal conjugate vaccines in all relapses were 40.0% (n=16) and 54.3% (n=19), respectively; and the coverage of reinfections were 23.5% (n=19) and 34.6% (n=28), respectively.

Seventeen PFGE patterns (related with 14 sequence types) were observed among the relapses, with the most frequent clonal complexes (CC) being CC15615A (22.9%), CC6315A,19F (17.1%), CC8610F (11.4%), CC8110A,19F (8.6%) and CC26013 (5.7%). Among reinfections, 56 different PFGE patterns were observed, and the most frequent clones were CC6315A (7.4%), CC3023F (7.4%), CC7713F (4.9%), CC15619 (4.9%), CC4223A,23F (3.7%), CC6210A (3.7%), CC9710A (3.7%), CC1917F (3.7%) and CC26013 (3.7%).

Only the CC15619 genotypes was associated with relapses (OR 5.8; 95% CI, 1.61–20.73). Serotype 19F was genetically heterogeneous [CC8819F (6.2%), CC8119F (2.9%), and CC6319F (2.9%)].

Antimicrobial consumption and susceptibility

Table 3 shows the activity of nine antimicrobials against pneumococci isolated from relapses and reinfections. Resistance to betalactams, fluoroquinolones and co-trimoxazole was higher among the strains that caused relapses than among those causing reinfections (P<0.01).

### Table 1. Distribution of the number of relapses and reinfections based on the time between episodes.

| Time between episodes (days) | Relapses (n=35) | Reinfections (n=81) | P-value |
|-----------------------------|----------------|---------------------|---------|
| ≤120                        | 20 (57.1%)     | 29 (35.8%)          | 0.033   |
| 121–240                     | 10 (28.6%)     | 27 (33.3%)          | 0.613   |
| >240                        | 5 (14.3%)      | 25 (30.9%)          | 0.061   |

### Table 2. Serotypes causing relapse and reinfection episodes of acute exacerbations in COPD patients.

| Serotype | Relapses (n=35) | Reinfections (n=81) | OR | 95% CI |
|----------|----------------|---------------------|----|--------|
| 9V       | 6 (17.1%)      | 2 (2.5%)            | 8.00 | 1.34–85.59 |
| 19F      | 6 (17.1%)      | 1 (1.2%)            | 16.11 | 1.84–767.20 |
| 15A      | 5 (14.3%)      | 7 (8.6%)            | 1.75 | 0.41–7.01 |
| 11A      | 4 (11.4%)      | 3 (3.7%)            | 3.32 | 0.53–23.95 |
| 3        | 3 (8.6%)       | 5 (6.2%)            | 1.42 | 0.21–7.82 |
| 6C       | 2 (5.7%)       | 0                   | infinite | 0.44–infinite |
| 22F      | 2 (5.7%)       | 3 (3.7%)            | 1.57 | 0.13–14.36 |
| 19A      | 2 (5.7%)       | 4 (4.9%)            | 1.17 | 0.10–8.59 |
| 35B      | 1 (2.9%)       | 1 (1.2%)            | 2.33 | 0.03–186.68 |
| 33F      | 1 (2.9%)       | 5 (6.2%)            | 0.45 | 0.01–4.24 |
| 23F      | 1 (2.9%)       | 2 (2.5%)            | 1.16 | 0.02–22.99 |
| 23A      | 1 (2.9%)       | 2 (2.5%)            | 1.16 | 0.02–22.99 |
| 14       | 1 (2.9%)       | 4 (4.9%)            | 0.57 | 0.01–6.03 |
| 16F      | 0              | 6 (7.4%)            | 0.00 | 0.00–1.93 |
| 7F       | 0              | 4 (4.9%)            | 0.00 | 0.00–3.51 |
| 38       | 0              | 4 (4.9%)            | 0.00 | 0.00–3.51 |
| 31       | 0              | 4 (4.9%)            | 0.00 | 0.00–3.51 |
| Non-typeable | 0       | 0                   | 0.00 | 0.00–3.51 |
| 6B       | 0              | 3 (3.7%)            | 0.00 | 0.00–5.63 |
| 10A      | 0              | 3 (3.7%)            | 0.00 | 0.00–5.63 |
| 35F      | 0              | 2 (2.5%)            | 0.00 | 0.00–12.39 |
| 23B      | 0              | 2 (2.5%)            | 0.00 | 0.00–12.39 |

*Serotypes 1, 9N/L, 12F, 15B/C, 17F, 18C, 24F, 29 and 34 were detected in only one reinfection episode.*

<https://10.1371/journal.pone.0059027.t001>
them was significantly associated with relapses. These results contrast, several genotypes expressed the serotype 19F and none of hence, this clone was associated with the relapse episodes. In Discussion

P. aeruginosa, H. influenzae available about the persistence of pneumococcal strain has been associated with a significantly increased risk of a new acute exacerbation [2], little information is

invasiveness of pneumococcal strains [4]. Thus, some serotypes have been associated with invasive pneumococcal disease or with acute exacerbations of COPD [3]. Although the isolation of a new pneumococcal strain has been associated with a significantly increased risk of a new acute exacerbation [2], little information is available about the persistence of S. pneumoniae isolates.

Our results agree with other reports in which reinfection during the episode prior to reinfection or relapse (n = 116) were beta-lactams (49.2%), fluoroquinolones (25.9%) or both (5.2%). Consumption of fluoroquinolones during the previous episode was higher in relapses than in reinfections (40.0% vs. 19.8%, respectively; P = 0.02), whereas, no differences in the beta-lactams consumption was observed (25.7% of relapses and 27.1% of reinfections; P = 0.872).

**Table 3. In vitro activity of nine antimicrobials against pneumococci isolated from relapses and reinfections**

| Antibiotic          | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | MIC range (mg/L) | % S | % I | % R | P-value<sup>a</sup> |
|---------------------|-------------------------|-------------------------|------------------|-----|----|----|-------------------|
| Penicillin          | 0.5–4                   | ≥0.03–4                 | 25.7<sup>b</sup> | 45.7 | 28.6 | 0.06 | 0.000             |
| Cefotaxime          | 0.12–1                  | ≥0.03–2                 | 68.6<sup>c</sup> | 28.6 | 2.9 | 0.05 | 0.000             |
| Ciprofloxacin<sup>a</sup> | 1–32                  | ≤0.5–32                 | 74.3             | –    | 25.7 | 0.5 | 0.02              |
| Levofloxacin        | ≤0.5–32                 | ≤0.5–32                 | 77.1             | 2.9  | 20.0 | 0.5 | 0.001             |
| Tetracycline        | ≤2–32                   | ≥2–32                   | 54.3             | 2.9  | 42.8 | ≤2  | 0.205             |
| Erythromycin        | ≤0.25–32                | ≤0.25–32                | 57.1             | 0    | 42.9 | ≤0.25 | 0.000             |
| Clindamycin         | ≤0.25–32                | ≤0.25–32                | 57.1             | 0    | 42.9 | ≤0.25 | 0.000             |
| Chloramphenicol     | ≤2–8                    | ≤2–8                    | 88.6             | 11.4 | ≤2  | 8   | 0.081             |
| Co-trimoxazole      | 2/38                    | >4/76                   | 45.7             | 5.7  | 48.6 | >4/76 | 0.000             |
|                     |                         |                        |                  |      |     |     |                   |

Clinical Laboratory Standard Institute (CLSI) breakpoints: Penicillin oral breakpoints: susceptible ≤0.06 mg/L, intermediate 0.12–1 mg/L and resistant ≥2 mg/L. Penicillin parenteral (non-meningitis) breakpoints: susceptible ≤2 mg/L, intermediate 4 mg/L and resistant ≥8 mg/L. Cefotaxime (meningitis) breakpoints: susceptible ≤1 mg/L, intermediate 2 mg/L and resistant ≥4 mg/L. Non-susceptibility to ciprofloxacin breakpoint MIC ≥4 mg/L, and susceptibility breakpoint ≤2 mg/L. <sup>a</sup>P-value comparing susceptible strains.

doi:10.1371/journal.pone.0059027.t003

The most frequent antimicrobials consumed by these patients during the episode prior to reinfection or relapse (n = 116) were beta-lactams (49.2%), fluoroquinolones (25.9%) or both (5.2%). Consumption of fluoroquinolones during the previous episode was higher in relapses than in reinfections (40.0% vs. 19.8%, respectively; P = 0.02), whereas, no differences in the beta-lactams consumption was observed (25.7% of relapses and 27.1% of reinfections; P = 0.872).

**Discussion**

Capsular type is known to play an important role in the invasiveness of pneumococcal strains [4]. Thus, some serotypes have been associated with invasive pneumococcal disease or with acute exacerbations of COPD [3]. Although the isolation of a new pneumococcal strain has been associated with a significantly increased risk of a new acute exacerbation [2], little information is available about the persistence of S. pneumoniae isolates.

In addition, differences in genotype distribution were also detected. All isolates that expressed the serotype 9V belonged to the Spain<sup>c</sup>-CC156; hence, this clone was associated with the relapse episodes. In contrast, several genotypes expressed the serotype 19F and none of them was significantly associated with relapses. These results suggest that capsular type, rather than genetic background, may play an important role in the persistence of pneumococci among COPD patients.

Most of the patients included in the study had severe or very severe COPD, suffering frequent episodes of acute exacerbation and they received multiple antibiotic courses [6]. Although there were no differences in the beta-lactam consumption among groups, the beta-lactam resistance rates were higher among relapse episodes. This finding could be explained because relapse episodes were caused by few multi-resistant clones (mainly CC156 and CC38). Whereas, strains causing reinfection episodes showed a higher genetic diversity including penicillin-susceptible and -resistant clones. However, we found an association between fluoroquinolone consumption and development of resistance. In fact, the development of fluoroquinolone resistance during or after an antimicrobial course has been largely described in the literature [7–8].

The proportion of serotypes covered by the 23<sup>â</sup>vPPV vaccine was high, especially those causing relapses. Unfortunately, vaccination data of patients included in the present study was not available; however, its protective efficacy in COPD populations is controversial since COPD adults respond differently than the general adult population, due to their impaired antibody response to the vaccine, the colonization of the lower respiratory tract, or the frequent use of inhaled corticosteroids [9]. In the other hand, conjugate vaccines (PV10 and PCV13) vaccine, which have an enhanced immunity potential, could prevent the 40% and a half of the overall relapse episodes, respectively.

The major limitations of our study are the low number of relapse episodes, and also that it is a retrospective study. Nonetheless, our study provides new data about the association of certain serotypes with the persistence of pneumococci and the ability to some clones, especially Spain<sup>c</sup>-CC156, to cause relapse episodes. In addition, our study suggests that new episodes that occurred within the first 3 months after a previous one, had higher probability to be caused by the same pneumococcal strain and this fact could help to give an adequate empirical therapy.
Further studies with a high number of recurrent episodes are now needed to investigate not only the role of capsular type in relapses of acute exacerbations, but also whether the pneumococcal conjugate vaccine 13 could be beneficial for COPD patients.

**Methods**

**Study design**

Pneumococci and other potential pathogens isolated from sputum samples were prospectively collected into our laboratory between 1995 and 2010, and were frozen at −80 °C for further analysis. Only pneumococci isolated from good quality sputum were considered (<10 squamous cells and >25 leukocytes per low-power field), with a predominance of Gram positive diplococci.

All COPD patients (n = 79) with two or more acute exacerbation episodes and seen at the Bellvitge University Hospital during the study period were included, after retrospective review of their computerized medical charts. Only those consecutive acute exacerbations which lasted for between four weeks and one year were included in the study.

The severity of airflow obstruction was categorized according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [10].

An acute exacerbation of COPD was defined as any sustained increase in respiratory symptomatology compared with the baseline situation requiring an increase in regular medication and hospital treatment. A ‘relapse’ episode was defined as two or more consecutive acute exacerbations caused by the same pneumococcus (identical serotype and genotype). When the consecutive episodes were caused by pneumococci with different serotype and Pulsed Field Gel Electrophoresis (PFGE) pattern they were defined as ‘reinfection’.

**Ethical statement**

This study and publication of the results were approved by the ‘Comité Étic d’Investigació Clínica del Hospital Universitari de Bellvitge’ and the written or oral informed consent was considered not necessary, because the source of bacterial isolates was anonymized and the study was retrospective.

**Serotyping and genotyping**

Serotyping was performed by multiplex PCR, using a previously described methodology [11]. All isolates were genotyped by PFGE. Multi Locus Sequence Typing (MLST) was performed on all relapse isolates in order to confirm the identity of the isolates [12–13].

**Antimicrobial susceptibility**

Antimicrobial susceptibility was tested by microdilution (STREHAE, Sensititre® [14]), following the Clinical Laboratory Standards Institute (CLSI) criteria [14]. The ciprofloxacin MIC of resistant strains (MIC ≥4 mg/L) was confirmed by E-test. S. pneumoniae ATCC49619 was used as the control strain.

**Statistical analysis**

Statistical analyses were carried out using SPSS 18 for Windows. The odds ratios (OR) and 95% confidence intervals (CI) were calculated, and Fisher’s exact test was used when appropriate. Two-sided P values <0.05 were considered statistically significant.

**Acknowledgments**

We acknowledge the use of the Streplococcus pneumoniae MLST web site at Imperial College London, funded by the Wellcome Trust. We wish to thank all the staff of Microbiology Laboratory of Hospital Universitari de Bellvitge who contributed to this project on a daily basis.

**Author Contributions**

Conceived and designed the experiments: AD JL RP CA. Performed the experiments: AD. Analyzed the data: AD SS IG RP AC. Contributed reagents/materials/analysis tools: JL. Wrote the paper: AD CA JL.

References

1. World Health Organization (2012) Chronic obstructive pulmonary disease. Fact sheet No. 315 Available: http://www.who.int/mediacentre/factsheets/fs315/en. Accessed 2012 June 6.

2. Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359: 2355–2363.

3. Sethi S, Evans N, Granj BJ, Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347: 465–471.

4. Brueggemann AB, Griffiths DT, Meats E, Perot T, Crook DW, et al. (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187: 1429–1432.

5. Domenach A, Aundany C, Calataud L, Santos S, Tubau F, et al. (2011) Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. J Antimicrob Chemother 66: 487–493.

6. Domenach A, Aundany C, Bahalobre L, Marti S, Calataud L, et al. (2012) Pneumococci can persistently colonize adult patients with chronic respiratory disease. J Clin Microbiol 50: 4047–4053.

7. De la Campa AG, Ferrandiz MJ, Tubau F, Pallares R, Manresa F, et al. (2003) Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob. Agents Chemother 47:1419–1422.

8. Davidson R, Cavalcanti R, Brunton JL, Bast DL, de Azavedo JC, et al. (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346: 747–750.

9. Schenkien JG, Nahm MH, Dransfield MT (2008) Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 133: 767–774.

10. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, et al. (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256–76.

11. Centers for Disease Control and Prevention (2012) PCR Deduction of Pneumococcal Serotypes. Available: http://www.cdc.gov/ncidod/biotech/ strep/prc.htm. Accessed 2012 July 5.

12. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 2233–2239.

13. Enright MC, Spratt BG. (1998) Stability in the evolutionary mixture: bacterial species defined by clonal complexes. Microbiology 144: 2537–2543.

14. Clinical Laboratory Standard Institute (2011) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement. Wayne, Pa: Clinical and Laboratory Standards Institute. CLSI/NCCLS document M100-S21. Vol 31.